Express News | PAVmed Inc: Files for Mixed Shelf Offering of up to $125 Mln

ReutersDec 20 17:17 ET

PAVmed Is Maintained at Buy by Ascendiant Capital

Dow JonesDec 9 04:35 ET · Ratings

PAVmed Analyst Ratings

BenzingaDec 9 04:22 ET · Ratings

Express News | PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $19 From $21

ReutersDec 9 02:31 ET

PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.

BenzingaNov 20 08:38 ET

Express News | Lucid Diagnostics And Subsidiary Of PAVmed Announced That It Has Submitted Its Complete Clinical Evidence Package For Its Esoguard Esophageal DNA Test To Molecular Diagnostics Program Seeking Medicare Coverage For Esoguard Esophageal DNA Test

BenzingaNov 20 08:00 ET